Nuclear medicine procedures expose you to small amounts of radiation, but the doses involved in diagnostic scans are low enough that the medical benefits almost always outweigh the risks. A typical nuclear medicine exam delivers between about 0.3 and 20 millisieverts (mSv), a range that overlaps with what you absorb from natural background radiation each year, which averages roughly 3 mSv.1PubMed. Effective doses in radiology and diagnostic nuclear medicine: a catalog That said, the safety picture gets more layered once you look at therapeutic doses, repeated imaging, vulnerable groups like children and pregnant women, and the long-term epidemiological data on cancer risk.
What Nuclear Medicine Actually Does
Nuclear medicine uses radioactive tracers, tiny amounts of radioactive material attached to molecules your body naturally handles, to create images of how organs and tissues function rather than just what they look like. The two main imaging techniques are PET (positron emission tomography) and SPECT (single-photon emission computed tomography). PET relies on tracers labeled with isotopes like fluorine-18 and carbon-11 to map metabolic activity, blood flow, and chemical uptake. SPECT uses gamma-emitting isotopes such as technetium-99m and iodine-123 to assess blood distribution and organ function.2PubMed Central. Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade These scans are used across oncology, cardiology, and neurology, and the tracers are chosen based on what metabolic process doctors need to see.
Beyond imaging, nuclear medicine has a therapeutic arm. Radioactive iodine has been used for decades to treat overactive thyroid and thyroid cancer. Newer treatments use radiolabeled molecules, small molecules, peptides, or antibodies, that carry therapeutic radiation directly to tumor cells. This approach, sometimes called radiotheranostics, pairs a diagnostic scan with a targeted therapy using the same molecular carrier, allowing doctors to confirm where the cancer is and then selectively irradiate it.3PubMed Central. Radiotheranostics in oncology: current challenges and emerging opportunities
Diagnostic Accuracy That Justifies the Exposure
The strongest argument for nuclear medicine’s safety is the clinical value it provides. A scan that catches cancer early, identifies a heart condition before a cardiac event, or rules out a dangerous diagnosis can be life-altering. The radiation dose only makes sense to weigh against the alternative of not having that information.
Consider bone metastases in breast cancer. In a prospective comparison, PET/MRI detected all patients with confirmed bone metastases at 100% sensitivity, while CT caught about 71% and conventional bone scintigraphy only about 29%.4PubMed Central. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients CT and scintigraphy also produced false-positive findings that PET/MRI avoided. Missing metastatic disease at staging changes the entire treatment plan, so the superior accuracy of the nuclear medicine-based approach has direct consequences for patient outcomes.
In cardiology, stress myocardial perfusion imaging with SPECT or PET has an extensive evidence base for predicting coronary artery disease events, with a particular advantage in higher-risk patients who already have established heart disease.5Journal of Nuclear Medicine. Risk Assessment and Predictive Value of Coronary Artery Disease Testing For these patients, the scan’s ability to predict future cardiac events and guide treatment often makes the radiation exposure a minor consideration relative to the risk of an undetected blockage.
Putting the Radiation Dose in Context
Radiation dose is measured in millisieverts (mSv), and for most people the useful comparison is natural background radiation, the cosmic rays, radon gas, and trace radioactivity in soil and food that expose you to roughly 3 mSv every year just by being alive. Most diagnostic nuclear medicine procedures fall within about 0.3 to 20 mSv.1PubMed. Effective doses in radiology and diagnostic nuclear medicine: a catalog A straightforward bone scan or thyroid uptake test sits at the low end. A PET/CT scan is toward the higher end, because it combines the tracer dose with the radiation from the CT component.
In pediatric patients with neuroblastoma, for instance, the mean effective dose from a single PET/CT exam was about 8 mSv from the CT portion alone, while the PET portion added roughly another 10 mSv of estimated cumulative dose per patient over the treatment course.6PubMed Central. Comparison of effective radiation doses from X-ray, CT, and PET/CT in pediatric patients with neuroblastoma using a dose monitoring program CT of PET/CT accounted for nearly half the cumulative dose in that study. That detail matters because it shows that a significant chunk of the radiation from a “nuclear medicine scan” can actually come from the CT component used for anatomical mapping, not the radioactive tracer itself.
A single scan at the high end of the range is still a small fraction of the dose thresholds where deterministic harm, like radiation burns or organ damage, becomes a concern. The worry at diagnostic levels is stochastic risk: the small statistical increase in lifetime cancer probability. Regulatory bodies generally estimate this risk using a model that assumes any radiation dose, no matter how small, carries some proportional cancer risk. Whether that model accurately captures what happens at very low doses remains debated among radiation scientists, but it serves as a conservative benchmark for keeping doses as low as reasonably achievable.
Long-Term Cancer Risk from Therapeutic Doses
Therapeutic nuclear medicine is a different story from diagnostic imaging. When radioactive iodine is used to treat hyperthyroidism or thyroid cancer, the administered doses are orders of magnitude higher than anything used in a scan. A large cohort study following patients with hyperthyroidism treated with radioactive iodine found positive dose-response relationships for cancer mortality after excluding deaths in the first five years. At a 100 milligray organ dose, the relative risk for breast cancer mortality was about 1.12, and for all solid cancers combined, about 1.06.7JAMA Internal Medicine. Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism Those numbers sound modest, and they are in absolute terms for any individual patient, but they are statistically significant across a large population followed for an average of 26 years.
This finding does not mean radioactive iodine therapy is unsafe. For patients with Graves’ disease or thyroid cancer, the alternatives, including lifelong medication or surgery with its own risks, carry their own downsides. It does mean that therapeutic nuclear medicine carries a real, measurable long-term risk that should be part of the informed consent conversation, especially for younger patients who have more remaining years of life for a potential cancer to develop.
For patients undergoing repeated diagnostic imaging, cumulative dose is also a concern. Researchers studying lymphoma patients, who may undergo numerous CT and PET scans during staging and follow-up, have used risk models to estimate lifetime cancer risk from cumulative imaging radiation.8Scientific Reports. Cumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma The estimated risk is small for any individual scan but adds up. This is one reason oncologists increasingly weigh when to switch from PET/CT to MRI for follow-up surveillance, especially in younger patients expected to live for decades after treatment.
When the Kidneys Become the Bottleneck
In targeted radionuclide therapy, the radiation is designed to concentrate in tumor cells. The challenge is that the molecules carrying that radiation are cleared through the kidneys, and some of the radioactive material gets reabsorbed and retained in the kidney’s proximal tubules. This renal retention can cause nephrotoxicity, which becomes the dose-limiting factor in many peptide-based and antibody-based therapies.9Journal of Nuclear Medicine. Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention In practical terms, this means physicians cannot keep escalating the therapeutic dose indefinitely, because the kidneys would suffer serious damage before the tumor received enough radiation to be eradicated. Strategies to reduce kidney uptake, such as co-infusing amino acids that compete for reabsorption, have become standard in many treatment protocols.
Non-Radiation Side Effects
People tend to focus on the radiation component, but radiopharmaceuticals are still drugs injected into your body, and like any drug they can trigger adverse reactions unrelated to radiation. These reactions are rare but real. They include the same types of hypersensitivity reactions you might see with any injected pharmaceutical: itching, hives, redness, bronchospasm, and gastrointestinal symptoms like vomiting and diarrhea.10Farmacia Hospitalaria. Adverse reactions to radiopharmaceuticals More severe anaphylactic reactions, mediated by IgE antibodies, have been described but are exceptionally uncommon. The takeaway is that if you have a history of allergic reactions to contrast agents or similar injected substances, mention it before your scan. Nuclear medicine departments are equipped to handle these events, but forewarning helps.
Children and the Heightened Sensitivity Question
Children are more sensitive to radiation than adults for two reasons: their cells are dividing more rapidly, and they have more years of remaining life during which a radiation-induced cancer could emerge. This dual vulnerability means that the same scan delivering the same effective dose poses a larger theoretical risk for a five-year-old than for a sixty-five-year-old.11Journal of Nuclear Medicine. Minimizing and Communicating Radiation Risk in Pediatric Nuclear Medicine
Pediatric nuclear medicine has responded with protocols specifically designed to reduce doses while preserving image quality. The guiding principle is to administer the minimum tracer activity needed for a diagnostic image, scaled to the child’s weight and the specific exam. Modern cameras with better sensitivity also help, since they can produce a usable image from less radioactivity. Parents sometimes refuse nuclear medicine scans for their children based on radiation fear alone, which is understandable but can lead to delayed diagnoses or the substitution of less informative tests. A conversation with the referring physician and the nuclear medicine specialist about the expected dose and the clinical need is a better path than blanket avoidance.
Breastfeeding and Pregnancy
Pregnancy is the clearest scenario where nuclear medicine procedures need careful scrutiny. A developing fetus is extremely radiosensitive, particularly during the first trimester, so elective nuclear medicine scans are generally avoided in pregnant patients unless the clinical urgency is high enough to justify the exposure.
Breastfeeding involves a different calculation. The radioactive tracer can pass into breast milk, but the extent and duration depend on the specific radiopharmaceutical. Guidance varies widely by procedure. Many technetium-99m studies require only a four-hour interruption to breastfeeding, largely because of concern about pertechnetate impurity that concentrates in breast tissue rather than because the labeled compound itself poses a major risk. An FDG PET scan calls for about twelve hours. At the other end, all iodine-131-labeled procedures and gallium-67 scans require breastfeeding cessation for at least three weeks.12Journal of Nuclear Medicine Technology. Duration of Breastfeeding Interruption in Nuclear Medicine Procedures Some studies require no interruption at all, including sodium fluoride PET and indium-111 octreotide scans. The variation is large enough that blanket advice to “pump and dump for 24 hours” after any nuclear medicine procedure is often wrong in both directions.
How Safe Is It for the Staff
If you have ever noticed a nuclear medicine technologist step behind a barrier or leave the room quickly, it is because occupational radiation exposure is carefully managed. A 19-year follow-up at one department found that the average annual dose for all workers was 0.7 mSv, and for those with measurable exposure above the minimum detection level, it was 2.2 mSv.13PubMed Central. Occupational exposure at the Department of Nuclear Medicine as a work environment: A 19-year follow-up A study at a major hospital monitoring 30 nuclear medicine staff confirmed that annual occupational doses were well below the 20 mSv annual limit, and extremity doses stayed well under the 500 mSv limit for hands.14Radiation Physics and Chemistry. Assessment of occupational exposure and radiation risks in nuclear medicine departments
Even the introduction of new PET/CT machines, which use higher-energy gamma-emitting isotopes, did not increase staff doses in one Lithuanian center’s analysis, suggesting that improvements in shielding, procedure design, and radiation safety culture have kept pace with the expanding technology.15PubMed. Occupational radiation exposure of health professionals and cancer risk assessment for Lithuanian nuclear medicine workers The people most exposed tend to be radiology technologists and nurses who handle syringes and position patients, with fingertip doses running two to three times higher than what a ring dosimeter on the hand measures. Still, these doses remain well within regulatory limits.
After Therapy, You Are Temporarily Radioactive
One safety dimension that surprises many patients is what happens after they leave the hospital. Diagnostic tracers decay quickly, often within hours, and pose negligible risk to people around you. Therapeutic doses are another matter. After radioactive iodine therapy for thyroid disease, or after treatment with lutetium-177 for neuroendocrine tumors, patients emit enough radiation to require temporary precautions.
Beta-emitting therapies are somewhat reassuring in one respect: the beta radiation has a short range and stays mostly confined to the body, so the external dose to family members is limited. The contamination risk comes from bodily fluids, urine in particular. Guidelines recommend wearing gloves when handling contaminated materials, closing the toilet lid before flushing, and not leaving soiled materials in shared bathrooms.16Journal of Nuclear Medicine. Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists For iodine-131 therapy specifically, the American Thyroid Association has published practice recommendations on precautions both within and outside the home, tailored to the administered dose and the patient’s living situation.17PubMed. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association Patients living with young children or pregnant women typically need to maintain more distance and for a longer duration than those in households with only adults.
Quality Control Behind the Scenes
A dimension of safety that patients rarely see is the quality control applied to the radiopharmaceuticals themselves. Before a tracer is injected, it undergoes checks for radiochemical purity, essentially confirming that the radioactive label is attached to the right molecule and not floating around as “free” radioactivity that would distribute unpredictably in the body. In a three-year review of over 2,200 preparations at one center, only six failed quality control, a failure rate of about 0.26%, and five of those were due to gross technical errors that were immediately corrected.18PubMed Central. Quality control on radiochemical purity in Technetium-99m radiopharmaceuticals labelling: three years of experience on 2280 procedures
European guidelines on good radiopharmacy practice lay out detailed requirements for hospital radiopharmacies, covering everything from the preparation environment to sterile filtration for more complex compounds made from non-licensed starting materials.19PubMed Central. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals The system is not infallible, but the error rate is genuinely low, and the regulatory framework is designed to catch problems before they reach a patient.
What Happens to the Radioactive Waste
Hospitals do not simply throw away radioactive materials. Short-lived isotopes like technetium-99m, which has a six-hour half-life, generate waste that can be mixed with normal hospital refuse after a 48-hour delay, by which point the radioactivity has decayed to negligible levels. Longer-lived isotopes require dedicated containers, date labeling, and storage for at least two months before monitoring and release.20PubMed Central. An overview of radioactive waste disposal procedures of a nuclear medicine department Liquid waste, primarily urine from patients in isolation wards after high-dose therapy, is routed to underground delay tanks where it decays for about two months before discharge into the sewer system, with monitoring to ensure radioactivity is below regulated limits. The system is unglamorous but effective, and the decay-in-storage approach works because the isotopes used in medicine have short enough half-lives that time alone renders the waste safe.
Communicating Risk Honestly
One of the persistent problems in nuclear medicine is not the radiation itself but how poorly it tends to be communicated. In many clinical cultures, the conversation defaults to “your doctor has ordered this scan,” with little explanation of what the radiation exposure means or how the scan’s benefits compare to its risks.21PubMed Central. Communication of radiation risk in nuclear medicine: Are we saying the right thing? This leaves patients relying on their own understanding, which is often shaped by associations with nuclear weapons and reactor disasters rather than by anything relevant to medical isotopes.
Research into how people perceive radiation risk suggests that abstract numbers like “5 mSv” mean almost nothing to most patients. More effective approaches include comparing the scan’s dose to familiar exposures, such as a number of days’ worth of background radiation, or expressing the additional cancer risk in concrete terms rather than in the language of probability. Some frameworks ask clinicians to acknowledge the uncertainty, explaining that the risk is thought to be very small and may in fact be zero at diagnostic doses, while also making clear that the scan is being recommended because the expected benefit to the patient’s care exceeds that risk.22PubMed Central. Fears, feelings, and facts: interactively communicating benefits and risks of medical radiation with patients That kind of honest framing does more for informed consent than either dismissing the radiation as trivial or overstating it as dangerous.